Abstract
Get full access to this article
View all access options for this article.
References
1.
Pani
F
,
Atzori
F
,
Baghino
G
,
Boi
F
,
Tanca
L
,
Ionta
MT
,
Mariotti
S
. 2015 . Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved? . Thyroid , 11 :1255 –1261 .
2.
Grünwald
V
,
Kalanovic
D
,
Merseburger
AS
. 2010 . Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach . World J Urol , 28 :343 –351 .
3.
Porta
C
,
Gore
ME
,
Rini
BI
,
Escudier
B
,
Hariharan
S
,
Charles
LP
,
Yang
L
,
DeAnnuntis
L
,
Motzer
RJ
. 2016 . Long-term safety of sunitinib in metastatic renal cell carcinoma . Eur Urol , 69 :345 –351 .
4.
Grünwald
V
,
Prpić
M
,
Murgić
J
,
Jazvić
M
,
Jakšić
B
,
Krilić
D
,
Bolanča
A
,
Kusić
Z
. 2014 . Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy . Anticancer Res , 34 :3177 –3184 .